<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3318">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429594</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-14</org_study_id>
    <nct_id>NCT04429594</nct_id>
  </id_info>
  <brief_title>Study of the Incidence of SARS-CoV-2 Infection (COVID-19)</brief_title>
  <acronym>CovImmune 2</acronym>
  <official_title>Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational cohort study that will define the prevalence and
      incidence of CA-SARS-Cov2 infection using serological and PCR tests in a group of subjects
      during deconfinement. The team wishes to include approximately 1000 subjects in this study.

      The health crisis through containment has also created unprecedented environmental conditions
      with the very clear decrease in economic activities and a consequent decrease in exposure to
      the main air pollutants. The aim is therefore to carry out a case-control study in which each
      subject will be his or her own control in unexposed condition (to PM2.5, PM10, NO...) then
      exposed (after the recovery of economic activity and the usual levels of air pollutants) and
      to measure the impact of these pollutants on the immune system and epigenetic markers taking
      into account seasonality.

      The occurrence of infectious, cardiovascular, allergic and autoimmune events will then be
      measured according to the immunological profiles measured at inclusion.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>positive serologies</measure>
    <time_frame>12 months</time_frame>
    <description>number of positive serologies</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronavirus Infections</condition>
  <arm_group>
    <arm_group_label>volonteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>blood sampling at J0, M6, M12, M24, M36, M48, M60</description>
    <arm_group_label>volonteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any major subject, voluntary, exposed to the public from 11 May 2020 informed of the
             study by partner institutions (Departmental Council 06), affiliated to a social
             security scheme,

        Exclusion Criteria:

          -  Subject protected by law under tutorship or guardianship, or who cannot participate in
             a clinical study under the terms of Article L. 1121-16 of the French Public Health
             Code
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara SEITZ, MCUPH</last_name>
    <phone>334 92 03 55 02</phone>
    <email>seitz-polski.b@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Barbara SEITZ- POLSKI</last_name>
      <phone>334.92.03.55.02</phone>
      <email>seitz-polski.b@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>barbara SEITZ POLSKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>sonia BOYER SUAVET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian PRADIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

